Reported 2 days ago
H.C. Wainwright has begun coverage of 89bio, Inc. (NASDAQ:ETNB) with a Buy rating and a price target of $32, highlighting the potential of its lead candidate, pegozafermin, which mimics a liver-expressed hormone beneficial for obesity and metabolic disorders. The company is advancing pegozafermin through several Phase 3 trials for liver conditions, with promising Phase 2B results showing improvements in fibrosis and liver health. While ETNB shows investment potential, the article suggests other AI stocks may offer better opportunities.
Source: YAHOO